Report Overview

Indian CAR-T cell Therapy Market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of xx% during the forecast period (2019-2028).

India is leading the CAR-T cell therapy market of this region due to growing research and development activities. The incidence of patients with cancer in India among males was 679,421 (94.1 per 100,000) and among females 712,758 (103.6 per 100,000) for the year 2020. One in 68 males (lung cancer), 1 in 29 females (breast cancer), and 1 in 9 Indians will develop cancer during their lifetime (0-74 years of age). Moreover, an increasing number of cases in the country, advancements is technology for advanced and reliable treatment for cancer diseases, growing pharmaceutical industries, and rise in the number of clinical studies drive the CAR-T cell market growth in India.



Market Drivers

Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the Indian CAR-T cell therapy market. Rising number of adults and children developing cancer is expected to lead to high demand for an effective and reliable therapeutic treatment approach for improvement of quality of patients lives. Moreover, increasing government initiatives for improving health care infrastructure and promoting research for cell therapy in cancer is fueling growth of the market. Growing investments made by the government and other private organizations are surging the T-cell therapy market growth over the analysis period. Increasing healthcare expenditure and increasing disposable income are fueling market growth over the forecasting framework.